Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, traded on the NASDAQ under the symbol PGNY, is a New York City–based company specializing in comprehensive fertility and family building benefits. The company partners with employers to design and administer programs that support employees through all stages of fertility treatment and family formation. By integrating clinical expertise, data analytics and personalized case management, Progyny aims to improve success rates and reduce overall costs associated with fertility care.

Progyny’s benefit offerings encompass a wide range of services, including in vitro fertilization (IVF), egg and embryo freezing, gestational carrier services, donor gametes, adoption assistance and genetic screening. The company’s model features a network of fertility specialists, digital tools for ongoing patient engagement and dedicated case managers who guide members through treatment plans. This combination of clinical oversight and data-driven insights enables employers and members to track outcomes and optimize care pathways.

Founded in the mid-2010s and publicly listed in 2020, Progyny has rapidly expanded its footprint across the United States, serving a diverse portfolio of large employers in industries such as technology, finance, retail and manufacturing. The company continually invests in research and partnerships to broaden access to cutting-edge reproductive technologies and telehealth services. Progyny’s leadership team includes seasoned executives with backgrounds in health care administration, benefits management and biotechnology, reflecting its commitment to innovation and quality in fertility care.

Key Stats

• Today's Range: $21.83 to $23.10
• 50-Day Range: $20.52 to $24.27
• 52-Week Range: $13.39 to $29.65
• Volume: 1.28 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $1.89 billion
• P/E Ratio: 38.60
• Dividend Yield: N/A
• Price Target: $24.82
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 36% of companies evaluated by MarketBeat, and ranked 719th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Progyny has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 38.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 38.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.22.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.30% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Progyny has recently increased by 10.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.30% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Progyny has recently increased by 10.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.79

News Sentiment

Progyny has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Progyny this week, compared to 8 articles on an average week.

Search Interest

4 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,037.00 in company stock.

Percentage Held by Insiders

Only 9.40% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PGNY Stock Analysis - Frequently Asked Questions

How have PGNY shares performed this year?

Progyny's stock was trading at $17.25 on January 1st, 2025. Since then, PGNY shares have increased by 27.5% and is now trading at $22.00.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings data on Thursday, May, 8th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by $0.28. The business's revenue was up 16.5% on a year-over-year basis.
Read the conference call transcript.

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's top institutional shareholders include Fort Washington Investment Advisors Inc. OH (1.45%), Leibman Financial Services Inc. (0.05%), State of Alaska Department of Revenue (0.05%) and GC Wealth Management RIA LLC (0.03%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 310
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $24.82
• High Price Target: $31.00
• Low Price Target: $17.00
• Potential Upside/Downside: +12.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.57
• Trailing P/E Ratio: 38.60
• Forward P/E Ratio: 36.67
• P/E Growth: 2.37
• Net Income: $54.34 million
• Net Margins: 4.33%
• Pretax Margin: 7.19%
• Return on Equity: 10.90%
• Return on Assets: 7.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $1.21 billion
• Price / Sales: 1.55
• Cash Flow: $0.33 per share
• Price / Cash Flow: 66.68
• Book Value: $4.96 per share
• Price / Book: 4.44

Miscellaneous

• Outstanding Shares: 85,718,000
• Free Float: 77,661,000
• Market Cap: $1.89 billion
• Optionable: Optionable
• Beta: 1.31